Compare Fortinet Inc (FTNT) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fortinet Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Fortinet Inc trades at $161.72 (market cap $118.78B), while State Street SPDR S&P Biotech ETF trades at $159.14. Which is the better fit depends on your goals.
| FTNT | XBI | |
|---|---|---|
Market Cap | $118.78B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $168.29 | $164.28 |
52-Week Low | $75.23 | $86.92 |
Enterprise Value | $115.21B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fortinet (FTNT) trades at $164.09, down slightly by 0.07% today, with strong technical momentum showing bullish moving average signals. The company demonstrates robust fundamentals with revenue growing from $6.0B in 2024 to $6.8B in 2025 and net income reaching $1.85B. Recent Q2 2026 earnings beat expectations with $0.90 EPS versus $0.746 expected, continuing a pattern of strong quarterly performance. Analyst consensus remains positive with a $174.50 price target representing 6% upside potential from current levels.
Fortinet presents a compelling growth story with cybersecurity demand accelerating amid AI adoption, though elevated valuation metrics (P/E 57.2, P/S 16.08) require continued execution. Key risks include competitive pressures in the cybersecurity space and the stock's premium pricing relative to historical norms. The combination of strong earnings momentum, institutional support, and positive industry trends supports a constructive outlook for patient investors.
XBI trades at $159.15, up 0.71% with a bullish technical signal from moving averages. The biotech ETF shows strong momentum with a 17% monthly gain, driven by positive clinical data and M&A activity. Analyst coverage remains limited with a single hold rating, while institutional interest grows with recent $793,000 investment from Bay Colony Advisors.
Outlook remains positive given biotech sector resurgence, though elevated RSI suggests near-term overbought conditions. Key risks include sector volatility and regulatory uncertainty, but AI-driven drug discovery and strong pipeline developments provide growth catalysts for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fortinet Inc
Fortinet is a cybersecurity vendor that sells products, support, and services to small and midsize businesses, enterprises, and government entities. Its products include unified threat management appliances, firewalls, network security, and its security platform, Security Fabric. Services revenue is primarily from FortiGuard security subscriptions and FortiCare technical support. At the end of 2021, products were 38% of revenue and services were 62% of sales. The California-based company sells products worldwide.
Read more on FTNT →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
